welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
mechanism of action: Non-steroidal agent to decrease inflammation
last updated: November 22, 2018
phase of development: Phase 2
Documented diagnosis of dystrophinopathy
Severe functional impairment
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyThis is an open-label study to assess th...
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)This is an open-label, extension study o...
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
Promising new therapy spares muscle loss in Duchenne muscular dystrophyBUFFALO, N.Y. — A promising therapy fo...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...